Sort   by:  
 Page size 
ProteomicsProteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases
Background MAP kinase inhibitor (MAPKi) therapy for BRAF mutated melanoma is characterized by high response rates but also development of drug resistance within a median progression-free survival (PFS) of 9 to 12 months. Understanding mechanisms of resistance and identifying effective therapeutic al...
ORGANISM(S): Homo sapiens (Human) 
2018-03-16 | PXD007592 | Pride
Melanoma Cerebral melanoma metastases Drug resistance Map kinase inhibitor Proteomics Braf mutation 
ProteomicsProteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases
Background MAP kinase inhibitor (MAPKi) therapy for BRAF mutated melanoma is characterized by high response rates but also development of drug resistance within a median progression-free survival (PFS) of 9 to 12 months. Understanding mechanisms of resistance and identifying effective therapeutic al...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
MSV000082948 | MassIVE
Transcriptomicsgene expression profiling of brain metastatic melanoma cell lines
Cerebral metastases occur in a majority of metastatic melanoma patients and are a major cause of mortality. Despite this, there is a poor understanding of the molecules/pathways that lead to the brain-metastatic phenotype. Studies designed to address this deficiency and test novel therapeutic approa...
ORGANISM(S): Homo sapiens 
2012-11-21 | E-GEOD-23601 | biostudies-arrayexpress
ProteomicsMulti omics evaluation of cutaneous melanoma cells and their cerebral metastasis from patient derived mouse xenografts suggest individually distinct adaptation strategies
Brain metastases of melanoma are associated with therapy resistance and poor prognosis. It is not fully understood whether and how the selection of cells capable of metastasizing into the brain is accompanied by the establishment of specific features. For the investigation of these questions, we mad...
ORGANISM(S): Homo sapiens (Human) 
2020-01-08 | PXD013765 | Pride
Proteome profiling Eicosanoids Xenograft model Brain metastasis Melanoma 
TranscriptomicsProgressing vs regressing melanoma metastases
We documented the transcriptional pattern of 3 progressing and 2 regressing synchronous melanoma metastases from the same patient following M-VAX treatment. Two-condition experiment, Progressing vs regressing metastases. 3 progressing and 2 regressing metastases extracted from the same patient after...
ORGANISM(S): Homo sapiens 
2010-09-11 | E-GEOD-24067 | biostudies-arrayexpress
UnknownProteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases.
Not available
S-EPMC5844114 | biostudies-literature
UnknownOutcomes in patients with BRAFV600-mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib.
Not available
S-EPMC10702308 | biostudies-literature
TranscriptomicsResponse to immunotherapy in melanoma metastasis
We have study 15 melanoma metastasis obtained from 2 different patients. Five metastases were obtained from patient 1 after M-VAX treatment (2 regressing and 3 progressing). Ten were obtained from patient 2, five after interferon treatment (1 progressing and 4 regreesing) and another 5 after M-VAX t...
ORGANISM(S): Homo sapiens 
2011-12-31 | E-GEOD-26383 | biostudies-arrayexpress
UnknownIncidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.
Not available
S-EPMC8258671 | biostudies-literature
UnknownEffectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS.
Not available
S-EPMC10732299 | biostudies-literature
Sort   by:  
 Page size